Diabet type 1. Insulin-dependent diabetes mellitus
Conditions
Interventions
Hematopoietic stem cells in 1 mili liter.
Treatment - Drugs
Hematopoietic stem cells in 1 mili liter
Sponsors
Endocrinology Metabolism Research Center
Eligibility
Sex/Gender
All
Age
6 Years to 41 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1) Informed written consents should be obtained from each patient , 2) Age between 6y-41) duration of disease up to 36 months, 4) blood glucose under 15mmol/l, 5) Diabetes in each patient should be in a a stage before start of any refractory complication . Exclusion criteria: 1) Acute vascular inflammation, 2) acute thrombosis, 3) recent retinal hemorrhage, 4) pulmonary hypertension, 5) corpulmonel, 6) B.M malignancy, 7) end stage diseases, infections, and 8) signs of refractory complications.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| FBS. Timepoint: In 4, 12, 24, 56 weeks after first injection. Method of measurement: mg/dl. blood sample.;HgA1C. Timepoint: In 4, 12, 24 ,56 weeks after first injection. Method of measurement: %total Hb. blood sample analysis.;C-peptid. Timepoint: In 4, 12, 24, 56 weeks after first injection. Method of measurement: ng/ml, serum analysis.;CD Markers. Timepoint: In 4, 12, 24, 56 weeks after first injection. Method of measurement: serum analysis, % lymphocyte.;Insulin dose. Timepoint: weekly, every other 2week, monthly, every other 3 month. Method of measurement: Mean dose of insulin injected in one week. | — |
Secondary
| Measure | Time frame |
|---|---|
| ?BMI. Timepoint: In 4,12,24.56weeks after first injection. Method of measurement: Kg/Cm*cm.;Hyperglycemia. Timepoint: Daily. Method of measurement: mg/dl, blood sample.;Hypoglycemia. Timepoint: Daily. Method of measurement: mg/dl, blood sample. | — |
Countries
Iran (Islamic Republic of)
Outcome results
None listed